TY - JOUR T1 - Assessment of the Demographic and Clinical Factors Affecting Time to Incidence of Cardiovascular Restenosis in Patients’ Undergone Angioplasty in Zanjan, Iran TT - بررسی عوامل جمعیت شناختی و بالینی مؤثر بر زمان بروز تنگی مجدد عروق کرونر در بیماران تحت آنژیوپلاستی شهر زنجان JF - jhpm.ir JO - jhpm.ir VL - 6 IS - 4 UR - http://jhpm.ir/article-1-823-en.html Y1 - 2017 SP - 25 EP - 33 KW - Cardiovascular Restenosis KW - Angioplasty KW - Drug Eluting Stent KW - Survival Analysis KW - Cox's Regression Model N2 - Introduction: Restenosis after stenting constitutes is one of the major concerns among cardiologists’ experts. This may lead to repetition of angioplasty, coronary artery bypass graft surgery, myocardial infarction, and even death. The present study, by using Cox's regression model aims at determine the demographic and clinical factors affecting time to incidence of cardiovascular restenosis in patients’ undergone angioplasty in Zanjan, Iran. Methods: In this descriptive longitudinal study, 421 patients who visited Zanjan's Ayatollah Mousavi hospital for drug eluting stent implantation between April 2009 and June 2011 are scrutinized with respect to the time of the incidence of restenosis. Next, demographic variables and patients' clinical records are entered into “Data Gathering Form of Patients’ Undergone Angioplasty”. Data is analyzed using Cox's regression and SPSS 21. Results: The mean time of restenosis incidence is 736 days and the rate of restenosis incidence is 30.4%. Hazard ratio of restenosis in unemployed patients is 1.39 times, in drug addicted patients 1.75 times, in patients with a history of hyperlipidemia 1.57 times, and in patients with chronic kidney disease is 1.58 times more than other patients (P < 0.05). Conclusions: This study indicated that the most important factors leading to the incidence of restenosis are unemployment, drug addiction and abuse, suffering from hyperlipidemia, and chronic kidney diseases. Accordingly, it is highly recommended to prevent patients from above-mentioned risk factors and plan a periodic and continuous follow-up for patients with any of these factors. M3 10.21859/jhpm-07024 ER -